Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director · Chief Executive Officer | August 17, 2026 | August 19, 2026 |
| CONMED CorpCNMD · Entity 4691 | Director | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 57,590 |
Reported balance
After 2026-08-17 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-08-17 · Grant · Acquired 57,590 · Balance 57,590 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12: 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 93,582 |
Reported balance
After 2026-08-17 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-08-17 · Grant · Acquired 93,582 · Balance 93,582 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F13: 93,582 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,544 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 8,544 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10: 8,544 restricted stock units vest on 8/15/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,569 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 23,569 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11: 11,785 restricted stock units vest on 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. |
| Common StockSEC Table I · non-derivative | Direct | 82,762 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 82,762 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 115,724 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 115,724 F1: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 25,944 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 25,944 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | Direct | 28,940 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 28,940 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 1,492 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 1,492 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 29,391 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 29,391 F2: Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.83 · Expires 2030-11-01 | Direct | 38,252 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 38,252 F3: Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.54 · Expires 2031-02-01 | Direct | 1,621 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 1,621 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.54 · Expires 2031-02-01 | Direct | 51,890 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 51,890 F4: Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.91 · Expires 2034-08-15 | Direct | 69,061 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 69,061 F5: Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.60 · Expires 2035-08-15 | Direct | 90,441 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 90,441 F6: Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 51,261 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 51,261 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 70,708 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 70,708 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
Filing footnotes · ownership attribution and instrument terms
F1: Fully exercisable.
F2: Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
F3: Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
F4: Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
F5: Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
F6: Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F8: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F9: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F10: 8,544 restricted stock units vest on 8/15/2027.
F11: 11,785 restricted stock units vest on 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
F12: 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029.
F13: 93,582 restricted stock units vest on 8/17/2029.
CONMED Corp
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Exercise / conversion · Acquired 500 · Balance 500 |
| RSUs (Restricted Stock Units)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2035-09-08 | Direct | 0 |
Reported balance
After 2026-09-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-08 · Exercise / conversion · Disposed 500 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 19:13 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionRSUs (Restricted Stock Units) · Derivative | 500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000816956-26-000105 · form4.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2035-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 19:13 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0000816956-26-000105 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 93,582 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000133 · form4.xml · derivative · entry 17 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,582 Underlying: Common Stock · 93,582 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F13 · derivative.exercise_date: 93,582 restricted stock units vest on 8/17/2029. F13 · derivative.expiration_date: 93,582 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 57,590 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000133 · form4.xml · derivative · entry 16 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,590 Underlying: Common Stock · 57,590 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029. F12 · derivative.expiration_date: 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 11,785 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 19 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,569 Underlying: Common Stock · 11,785 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F14 · derivative.exercise_date: 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. F14 · derivative.expiration_date: 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 8,543 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 16 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,544 Underlying: Common Stock · 8,543 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. F11 · derivative.expiration_date: 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerPerformance Stock Options (Right to Buy) · Derivative | 24,324 | $0.00 Strike: $68.54 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 13 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,621 Underlying: Common Stock · 24,324 shares Expires 2031-02-01 F8 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,621 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerPerformance Restricted Stock Units · Derivative | 8,835 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 12 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,835 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 588 performance RSUs. The remainder of the performance RSUs were forfeited. F7 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 588 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 588 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 11 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,835 Underlying: Common Stock · 588 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 588 performance RSUs. The remainder of the performance RSUs were forfeited. F7 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 588 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerPerformance Stock Options (Right to Buy) · Derivative | 22,389 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 8 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,492 Underlying: Common Stock · 22,389 shares Expires 2030-08-15 F4 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,492 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerPerformance Restricted Stock Units · Derivative | 8,319 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 7 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,319 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 554 performance RSUs. The remainder of the performance RSUs were forfeited. F3 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 554 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 554 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 6 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,319 Underlying: Common Stock · 554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 554 performance RSUs. The remainder of the performance RSUs were forfeited. F3 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 554 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 10,821 | $72.40 | $783,440.40 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,762 Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 21,470 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 20:11 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0000914190-26-000106 · form4.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 20:11 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 28,686 | $72.07 | $2,067,400.02 |
DisclosureSEC source: 0000914190-26-000106 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,113 Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 20:11 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 35,000 | $47.60 | $1,666,000.00 |
DisclosureSEC source: 0000914190-26-000106 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:17 UTC | CONMED Corp CNMD · Entity 4691 | GrantRSUs (Restricted Stock Units) · Derivative | 5,772 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000816956-26-000071 · form4.xml · derivative · entry 1 Kelderman Kim · CIK 0001739054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,772 Underlying: Common Stock · 5,772 shares Expires 2036-06-01 F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. Read SEC document |
| May 05, 2026 Filed May 7, 2026 21:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,692 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0000914190-26-000088 · form4.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 26,692 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 05, 2026 Filed May 7, 2026 21:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 23,951 | $56.68 | $1,357,542.68 |
DisclosureSEC source: 0000914190-26-000088 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,799 Read SEC document |
| May 05, 2026 Filed May 7, 2026 21:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 26,692 | $47.60 | $1,270,539.20 |
DisclosureSEC source: 0000914190-26-000088 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 22:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,344 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0000914190-26-000081 · form4.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,692 Underlying: Common Stock · 11,344 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 22:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 1,363 | $58.58 | $79,844.54 |
DisclosureSEC source: 0000914190-26-000081 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,058 Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 22:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 11,344 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000081 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,500 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0000914190-26-000070 · form4.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,036 Underlying: Common Stock · 36,500 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 32,088 | $58.66 | $1,882,282.08 |
DisclosureSEC source: 0000914190-26-000070 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,077 Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:19 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 36,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000070 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 2,303 | $62.57 | $144,098.71 |
DisclosureSEC source: 0000914190-25-000031 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,665 Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 20:13 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 6,227 | $0.00 Strike: $53.83 | $0.00 |
DisclosureSEC source: 0000816956-25-000040 · form4.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,227 Underlying: Common Stock · 6,227 shares Expires 2035-09-08 F2 · ownership.direct: The stock options were granted under the 2025 Long-Term Incentive Plan of CONMED Corporation (the "Company) and generally vest 100% 1 year from the grant date. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 20:13 UTC | CONMED Corp CNMD · Entity 4691 | GrantRSUs (Restricted Stock Units) · Derivative | 500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000816956-25-000040 · form4.xml · derivative · entry 1 Kelderman Kim · CIK 0001739054 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 500 shares Expires 2035-09-08 F1 · ownership.direct: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. F2 · ownership.direct: The stock options were granted under the 2025 Long-Term Incentive Plan of CONMED Corporation (the "Company) and generally vest 100% 1 year from the grant date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 90,441 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001062993-25-014700 · form4.xml · derivative · entry 19 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,441 Underlying: Common Stock · 90,441 shares Expires 2035-08-15 F12 · derivative.exercise_date: Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 35,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014700 · form4.xml · derivative · entry 18 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,354 Underlying: Common Stock · 35,354 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. F11 · derivative.expiration_date: 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantPerformance Restricted Stock Units · Derivative | 70,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014700 · form4.xml · derivative · entry 17 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,708 Underlying: Common Stock · 70,708 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 8,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014700 · form4.xml · derivative · entry 15 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,087 Underlying: Common Stock · 8,543 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. F8 · derivative.expiration_date: 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 4,305 | $53.60 | $230,748.00 |
DisclosureSEC source: 0001062993-25-014700 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,968 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 8,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014700 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 20:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 48,176 | $0.00 Strike: $44.33 | $0.00 |
DisclosureSEC source: 0001062993-25-013134 · form4.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,176 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 20:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 43,649 | $53.12 | $2,318,634.88 |
DisclosureSEC source: 0001062993-25-013134 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,730 Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 20:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 48,176 | $44.33 | $2,135,642.08 |
DisclosureSEC source: 0001062993-25-013134 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,132 | $0.00 Strike: $44.33 | $0.00 |
DisclosureSEC source: 0001062993-25-012967 · form4.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,176 Underlying: Common Stock · 36,132 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 32,933 | $51.42 | $1,693,414.86 |
DisclosureSEC source: 0001062993-25-012967 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,203 Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 36,132 | $44.33 | $1,601,731.56 |
DisclosureSEC source: 0001062993-25-012967 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,392 | $0.00 Strike: $37.70 | $0.00 |
DisclosureSEC source: 0001062993-25-001237 · form4.xml · derivative · entry 4 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,392 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,661 | $77.95 | $129,479.93 |
DisclosureSEC source: 0001062993-25-001237 · form4.xml · nonDerivative · entry 3 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,004 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.69 to $78.08 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 11,731 | $77.19 | $905,533.49 |
DisclosureSEC source: 0001062993-25-001237 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,665 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.67 to $77.66 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 13,392 | $37.70 | $504,878.40 |
DisclosureSEC source: 0001062993-25-001237 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:47 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 2,430 | $75.31 | $183,003.30 |
DisclosureSEC source: 0001062993-24-018334 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,004 Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:05 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,492 | $0.00 Strike: $66.97 | $0.00 |
DisclosureSEC source: 0001062993-24-015997 · form4.xml · derivative · entry 5 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,724 Underlying: Common Stock · 1,492 shares Expires 2027-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:05 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,492 | $66.97 | $99,919.24 |
DisclosureSEC source: 0001062993-24-015997 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 69,061 | $0.00 Strike: $74.91 | $0.00 |
DisclosureSEC source: 0001062993-24-015385 · form4.xml · derivative · entry 19 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,061 Underlying: Common Stock · 69,061 shares Expires 2034-08-15 F12 · derivative.exercise_date: Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.